Delivery Order SPE2DB20D2001-SPE2DB25FPNEB
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,228.25 delivery order on August 29, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning the award was competitively issued. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $9,777.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of July 22, 2025. This is a competitively awarded, non-set-aside contract with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single requisition fulfillment under AmerisourceBergen's existing contract vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,632.54 to AmerisourceBergen Drug Corp for the supply of Mounjaro 12.5 mg/0.5 mL pens on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed price delivery order represents a single-source procurement with no set-aside designation, issued under a competitive contracting mechanism. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,990.49 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pens on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price, non-competitive delivery order represents a small-value pharmaceutical procurement executed under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The...
- The Defense Logistics Agency awarded a $3,069.43 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injections with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's broader pharmaceutical supply agreements with DLA. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $28,019.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 ml pens on August 6, 2025, with completion scheduled for August 7, 2025. The delivery will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,456.89 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 mL pens. This firm fixed-price, competitively awarded delivery order was issued on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's competitive standing...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors on September 5, 2025. This competitively awarded, non-set-aside contract has a ceiling value of $3,069.11 and is structured as a firm fixed price delivery order with an ultimate completion date of September 8, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $8,703.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Mounjaro 5 mg/0.5 ml pens. The contract, which is non-set-aside and competitively awarded, has an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $16,728.19 on September 2, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen (0.5 mL) to be delivered to Conshohocken, Pennsylvania. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA. The contract is classified as a child award, indicating it is issued...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPNEBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,372.09 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pens on July 18, 2025, with a completion date of July 21, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreement with the DLA. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's primary indefinite delivery contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion and extending through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceuticals, medical devices, and specialized healthcare commodities to support military and federal healthcare systems worldwide. Mounjaro, a diabetes treatment medication, falls within the company's extensive portfolio of brand-name and generic pharmaceutical products delivered through the DLA Medical Supply Chain to support Defense Health Agency, U.S. Coast Guard, and other government healthcare entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 7/18/25 |